07:56 AM EDT, 09/18/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Biocon Biologics Ireland's Pebrilzo to treat breast cancer, according to a Friday release. The drug, which is a biosimilar to Roche's (RO.SW) Perjeta, is intended for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of human epidermal growth factor receptor 2-positive, locally advanced, inflammatory, or early stage breast cancer, as well as adjuvant treatment of adults with HER2-positive early breast cancer, both at high risk of recurrence. It is also indicated for use in combination with trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. The European Commission is expected to issue its final decision in the near future.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.